Key result
Dopamine (DA1 and DA2) receptor agonists have been shown to decrease blood pressure in hypertensive patients, though clinical data reveals problems in their use.
Why the study?
Do DA1 and DA2 receptor agonists reduce blood pressure in hypertensive patients?
Do DA1 and DA2 receptor agonists reduce blood pressure in hypertensive patients?
DA1 and DA2 receptor agonists show potential for lowering blood pressure in hypertension, but their clinical application is currently limited by associated problems.
Problems limit clinical use of DA1/DA2 agonists; leaves open development of better-tolerated agents for hypertension.
Will dopamine (DA) agonists have a role in the treatment of hypertension? Recent advances of medicinal chemistry and receptor pharmacology have suggested a positive answer. First, the division of DA receptors into two subtypes, DA1 and DA2, and the differentiation of these receptors from other receptors have resulted in the synthesis of relatively selective agonists and antagonists. Second, agonists of DA1 and DA2 receptors have been shown to decrease blood pressure in experimental animals and hypertensive patients. Review of clinical data with DA1, DA2, and combination of DA1 and DA2 agonists not only has demonstrated efficacy, but has revealed problems in the use of these compounds. Finally, possible solutions of these problems will be discussed.
No takes yet. Share an insight, caveat, or question.
Goldberg et al. (1987) conducted a review in Hypertension. DA1 and DA2 receptor agonists was evaluated on Blood pressure. Dopamine (DA1 and DA2) receptor agonists have been shown to decrease blood pressure in hypertensive patients, though clinical data reveals problems in their use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: